Cubist Systematic Strategies, LLC Kronos Bio, Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.73 - $1.38 $7,385 - $13,961	-10,117 Reduced 33.4%	20,174 $25,000
Q1 2024 May 15, 2024	BUY	$1.02 - $1.3 $30,896 - $39,378	30,291 New	30,291 $39,000
Q2 2023 Aug 14, 2023	BUY	$1.24 - $1.92 $2,339 - $3,623	1,887 Added 16.14%	13,578 $23,000
Q1 2023 May 15, 2023	BUY	$1.34 - $2.62 $3,868 - $7,563	2,887 Added 32.79%	11,691 $17,000
Q4 2022 Feb 14, 2023	SELL	$1.44 - $3.44 $31,825 - $76,027	-22,101 Reduced 71.51%	8,804 $14,000
Q3 2022 Nov 14, 2022	SELL	$3.35 - $5.55 $6,840 - $11,333	-2,042 Reduced 6.2%	30,905 $104,000
Q2 2022 Aug 15, 2022	BUY	$3.12 - $7.52 $102,794 - $247,761	32,947 New	32,947 $120,000
Q1 2022 May 16, 2022	SELL	$6.26 - $14.42 $201,759 - $464,756	-32,230 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$11.35 - $21.18 $365,810 - $682,631	32,230 New	32,230 $438,000
Q3 2021 Nov 15, 2021	SELL	$18.17 - $24.7 $143,633 - $195,253	-7,905 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$20.08 - $29.02 $158,732 - $229,403	7,905 New	7,905 $189,000

19.8M

9.3K

100

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $48.8M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.